# 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes

> **NCT00318656** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 23 (actual)

## Conditions studied

- Non-Insulin-Dependent Diabetes Mellitus

## Interventions

- **DRUG:** rosiglitazone-metformin fixed dose combination
- **DRUG:** metformin + glimepiride

## Key facts

- **NCT ID:** NCT00318656
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2007-10
- **Final completion:** 2007-10
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2009-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00318656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00318656, "24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT00318656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*